Streptococcal C5a peptidase vaccine
AssigneeRegents of the University of Minnesota
InventorsPaul Patrick Cleary, Deborah K. Stafslien
Life of this patent
Estimating the term…
Abstract
Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
Claims11
An isolated and purified enzymatically inactive streptococcal C5a peptidase (SCP) which is a variant of a wild-type SCP, wherein the variant is said wild-type SCP having amino acid substitutions at its amino acid residues 130 and 512.
Dependencies are inferred from the claim text.